Published in final edited form as:

Conf Proc IEEE Eng Med Biol Soc. 2017 July ; 2017: 4041–4045. doi:10.1109/EMBC.2017.8037743.

Label-Free Hyperspectral Imaging and Quantification Methods for Surgical Margin Assessment of Tissue Specimens of Cancer Patients

Baowei Fei,

Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA.

Guolan Lu,

Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA.

Martin T. Halicek, Xu Wang,

Department of Otolaryngology, Emory University School of Medicine, Atlanta, GA.

Hongzheng Zhang,

Department of Otolaryngology, Emory University School of Medicine, Atlanta, GA.

James V. Little,

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.

Kelly R. Magliocca,

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.

Mihir Patel,

Department of Otolaryngology, Emory University School of Medicine, Atlanta, GA.

Christopher C. Griffith,

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.

Mark W. El-Deiry, and

Department of Otolaryngology, Emory University School of Medicine, Atlanta, GA.

Amy Y. Chen

Department of Otolaryngology, Emory University School of Medicine, Atlanta, GA.

Abstract

Hyperspectral imaging (HSI) is a relatively new modality in medicine and can have many potential applications. In this study, we developed label-free hyperspectral imaging for tumor margin assessment. HSI data, hypercube (x, y, λ) , consists of a series of images of the same field of view

that are acquired at different wavelengths. Every pixel in the hypercube has an optical spectrum. We collected surgical tissue specimens from 16 human subjects who underwent head and neck (H&N) cancer surgery. We acquired both HSI, autofluorescence images, and fluorescence images with 2-NBDG and proflavine from the specimens. Digitized histologic slides were examined by an H&N pathologist. We developed image preprocessing and classification methods for HSI data and differentiate cancer from benign tissue. The hyperspectral imaging and classification method was able to distinguish between cancer and normal tissue from oral cavity with an average accuracy of $90\pm 8\%$, sensitivity of $89\pm 9\%$, and specificity of $91\pm 6\%$. This study suggests that label-free hyperspectral imaging has great potential for surgical margin assessment in tissue specimens of H&N cancer patients. Further development of the imaging technology and quantification methods is warranted for its application in image-guided surgery.

I. Introduction

Surgery plays a major role in treating cancer and cures approximately 45% of all cancer patients [1, 2]. To cure a cancer patient by surgery, the surgeon needs remove the entire tumor during surgery. Unfortunately, up to 39% of patients who undergo surgery leave the operating room with positive or close margins [1, 3, 4]. It has been reported that a complete resection is a major predictor of patient survival for solid cancers [5]. Various methods have been developed for tumor margin assessment. Visual appearance and palpation are often used by a surgeon to differentiate between malignant and benign tissue [6]. However, this assessment is subjective and inaccurate. Intra-operative frozen tissue is commonly used to assess positive margin at initial surgery [7]. Small samples from the surgical bed are selected to evaluate presence or absence of residual cancer [8]. However, intraoperative frozen section diagnosis may suffer from errors that occur during sampling and histological interpretation. In addition, histological processing can take time [9], which is labor intensive and prolongs surgery time. Fluorescence imaging guided cancer resection has been shown to improve the number of complete resections [10-16]. However, fluorescence-based approaches require the injection of a fluorescence imaging agent during surgery and the agent needs to be approved by the U.S. Food and Drug Administration. There are clinical needs to develop label-free imaging technology and quantification methods to aid decision making during image-guided surgery.

Hyperspectral imaging (HSI), also called imaging spectrometer [17], was developed for remote sensing and has been explored for various applications by NASA [18]. With the advantages of acquiring two dimensional images across a wide range of electromagnetic spectra, HSI has been applied to numerous areas including vegetation and water resource control [19] [20], food quality and safety control [21] [22], forensic medicine [23][24], and biomedical area [25][26].

Hyperspectral imaging, as a label-free imaging technology, does not require a contrast agent and offers great potential for objective assessment of cancer margins. Light delivered to the biological tissue undergoes scattering from inhomogeneity of biological structures and absorption primarily in hemoglobin, melanin and water as it propagates through tissue [27] [28]. The tissue absorption, fluorescence and scattering characteristics change with the

progression of diseases [29]. The reflected, fluorescent and transmitted lights from tissue, where are captured by HSI, carry diagnostic information about tissue pathology [30] [31] [29, 32]. Recent advancements of hyperspectral cameras, image analysis methods and computational power make many exciting applications possible, for example, cancer detection and image-guided surgery [33].

In this study, we developed hyperspectral image preprocessing and quantification methods to distinguish tumor from benign tissue. We evaluated the hyperspectral imaging and classification method in surgical tissue specimens from head and neck cancer patients who underwent surgery.

II. Tissue Collection and Imaging Experiments

A. Tissue Collection and Histological Processing.

Human subjects who underwent head and neck cancer surgery at Emory University Hospitals Midtown were recruited into the study. The study protocol was approved by the Institutional Review Board of Emory University. During surgery, fresh surgical specimens were collected and sent to pathology for histological assessment. Three tissue samples, *i.e.*, *i)* clinically visible tumor, *ii)* surrounding benign tissue, and *iii)* tumor with adjacent benign tissue, were collected from the main specimen of each consented subject.

Each tissue specimen was transported to the research laboratory for hyperspectral and fluorescence imaging experiments, as described in the next section. After imaging, the resected specimen were fixed in formalin overnight and then sent to pathology for the standard histologic processing with hematoxylin and eosin (H&E) staining. The pathologic slides were digitally scanned, and an experienced pathologist outlined the tumor border on the digitized images for validation

B. Imaging System and Image Acquisition

We used a Maestro (PerkinElmer Inc., Waltham, MA) imaging camera to acquire the hyperspectral dataset. This wavelength-scanning system consists of a Xenon light source, a solid-state liquid crystal filter and a 12-bit high-resolution charge-coupled device (CCD). Details about this system has been described in our previous papers [34] [35]. This system is capable of obtaining reflectance images over the range of 450 - 950 nm, as well as fluorescence images under different excitation light sources [36].

Each tissue specimen was scanned using the following steps: *1)* Acquire white and dark reference hypercube before tissue imaging. White reference image cubes were acquired by placing a standard white reference board in the field of view. The dark reference cubes were acquired by keeping the camera shutter closed. *2)* Acquire reflectance hyperspectral images of the specimen from 450-900 nm with 5 nm intervals. *3)* Acquire fluorescence imaging with 2-NBDG (Cayman Chemical, Ann Arbor, Michigan) by incubating tissue, as described in [37]. *4)* Acquire fluorescence imaging with proflavine (Sigma Aldrich, St. Louis, Missouri) similarly as described in Step *3)* above.

III. Quantitative Image Analysis Methods

Fig. 2 shows the flowchart of the hyperspectral image processing, feature extraction, image classification, and cross validation steps, as described in details below.

A. Data Normalization

The normalization is to remove the spectral non-uniformity of the illumination device and the influence of dark current. The raw data is normalized using the following equation:

$$I_{reflect}(\lambda) = \frac{I_{raw}(\lambda) - I_{dark}(\lambda)}{I_{white}(\lambda) - I_{dark}(\lambda)}$$

Where $I_{reflect}(\lambda)$ is the calculated normalized reflectance value at the wavelength λ . $I_{raw}(\lambda)$ is the intensity value of the sample pixel. $I_{white}(\lambda)$ and $I_{dark}(\lambda)$ are the corresponding pixel intensities from the white and dark reference images at the wavelength λ .

B. Glare Detection and Removal

Glare was usually from the specular reflection of the moist tissue surface and the region does not contain useful diagnostic information of the tissue. As we reported in [38], the glare detection method includes the three steps: i) Estimate the first-order derivatives of spectral curves with a forward difference method; ii) Calculate the standard deviation (SD) of each derivative curve and generate an SD image for each hypercube. Glare pixels show higher SD than normal pixels. iii) Compute the intensity histogram of each SD image, fit the histogram with a loglogistic distribution, and then experimentally identify a threshold that separates glare and non-glare pixels.

C. Hyperspectral Image Classification

The classification step is to differentiate tumor pixels from normal tissue. A 2-class (tumor vs. normal tissue) classification was performed for each pixel on the HSI image. To reduce computational time without reducing accuracy, spectral curves were averaged in non-overlapping blocks of 5×5 to yield a spectral signature per block. Blocks containing glare pixels were excluded from classification process. We extract features from the hyperspectral data. The extracted spectral features included i) first-order derivatives of each spectral curve, which reflect the variations of spectral information across the wavelength range; ii) second-order derivatives of each spectral curve, which reflect the concavity of the spectral curve; iii) mean, stand deviation (std), and total reflectance at each pixel, which summarize the statistical characteristics of the spectral fingerprint; and iv) Fourier coefficients (FCs), which were initially found to be effective for target detection in the remote sensing field. For HSI classification, we implemented ensemble linear discriminant analysis (LDA) and support vector machine (SVM) using MATLAB (MathWorks, Natick, MA). After classification, each block on the image was assigned a label as cancerous or normal.

D. Pathological Validation

Pathologic images of the same surgical specimen were used to validate the cancer detection of hyperspectral image classification. On the digitized H&E-stained pathological images, the tumor margin was outlined by an experienced H&N pathologist. To assess the performance of the classification, we chose the regions of interest (ROIs), where the tumor or normal tissue were histopathologically confirmed by the pathologist, for analysis and validation.

The accuracy, sensitivity and specificity of the classifiers for each patient were calculated based on the number of correctly classified tumor and normal pixels/blocks of all the specimens belonging to the patient. The accuracy, sensitivity, and specificity are defined in the following equations (TN: true negative, TP: true positive, FP: false positive, FN: false negative):

$$\text{Accuracy} = \frac{TP + TN}{TP + FP + FN + TN};$$

$$\text{Sensitivity} = \frac{TP}{TP + FN}; \text{Specificity} = \frac{TN}{TN + FP}$$

IV. Results

We collected three types of tissue specimens from each of 16 human subjects, which include: *i*) Clinically visible tumor tissue without necrosis, *ii*) benign tissue, and *iii*) Tumor with adjacent benign tissue at the tumor-benign interface. Fig. 2 shows the three tissue specimens and their corresponding spectral curves. The three types of tissue demonstrate different spectral curves

For each subject, we used the images of the tumor and benign tissue to train the classification algorithms and then used the tumor with adjacent benign tissue to test the performance of the classification methods. In another word, the classification method built the training model with the spectral features extracted from the tumor and benign tissue and was then evaluated on the tumor-benign interface tissue of the same patient. Using the reflectance spectra from hyperspectral imaging, the hyperspectral imaging method was able to distinguish between cancer and normal tissue of the oral cavity with an average accuracy of $90 \pm 8\%$, sensitivity of $89 \pm 9\%$, and specificity of $91 \pm 6\%$.

Fig. 3 shows the photographs of the tumor and normal tissue as well as the tumor with adjacent normal tissue for a tongue cancer patient. The corresponding histological slides, hyperspectral images, autofluorescence images, fluorescence images with the vital dyes 2-NBDG and Proflavine are also shown for the comparison. In our preliminary results of these 16 human subjects, hyperspectral imaging outperformed autofluorescence imaging, 2-NBDG and proflavine fluorescence imaging for cancer detection on the surgical specimens. The tumor margin as assessed by the classification method was close to that of the histological image outlined by the pathologist.

V. Conclusion

Hyperspectral imaging is a label-free imaging technology that does not require the injection of an imaging contrast agent. It offers potential for noninvasive detection of cancer and for rapid assessment of surgical tissue specimens. Our quantitative image analysis methods are able to distinguish cancer from benign tissue in fresh surgical specimens of head and neck cancer patients.

In this study, we used the tumor and normal tissue from the same patient to train the classification and then to classify the tumor tissue with adjacent normal tissue. This approach provides reliably results and high accuracy for differentiating tumor from normal tissue. This approach is reasonable during surgery because this technology is to help the surgeon to differentiate the tumor margin while the clinician normally knows the tumor core but is not certain about the boundary of the tumor. We are also testing another approach that uses different patients' data to train the classification and then test the method on the new patient. This requires a large database and we are collecting tissue from more than 120 patients. The combination of the two approaches may be able to provide a useful tool for the surgeon to achieve complete resection and thus improve survival and outcome.

Acknowledgment

This research is supported in part by NIH grants (CA176684, R01CA156775, and CA204254) and by Developmental Funds from the Winship Cancer Institute of Emory University under award number P30CA138292.

References

- [1]. Singhal S, Nie SM, and Wang MD, "Nanotechnology Applications in Surgical Oncology," in Annual Review of Medicine. vol. 61, ed, 2010, pp. 359–373.
- [2]. De Grand AM and Frangioni JV, "An operational near-infrared fluorescence imaging system prototype for large animal surgery," Technology in Cancer Research & Treatment, vol. 2, pp. 553–562. 12 2003. [PubMed: 14640766]
- [3]. Vaidya A, Hawke C, Tiguert R, Civantos F, and Soloway M, "Intraoperative T staging in radical retropubic prostatectomy: is it reliable?," Urology, vol. 57, pp. 949–54, 5 2001. [PubMed: 11337301]
- [4]. Nguyen QT and Tsien RY, "Fluorescence-guided surgery with live molecular navigation - a new cutting edge," Nat Rev Cancer, vol. 13, pp. 653–62, 9 2013. [PubMed: 23924645]
- [5]. Gebitekin C, Gupta N, Satur C, Olgac G, Martin P, Saunders N, et al. "Fate of patients with residual tumour at the bronchial resection margin," European journal of cardiothoracic surgery, vol. 8, p. 339, 1994. [PubMed: 7946410]
- [6]. Keereweere S, Kerrebijn JF, Driel PAA, Xie B, Kaijzel E, Snoeks TA, et al., "Optical Image-guided Surgery—Where Do We Stand?," Molecular Imaging and Biology, vol. 13, pp. 199–207. 2011/4/01 2011. [PubMed: 20617389]
- [7]. Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, et al., "Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival," Proceedings of the National Academy of Sciences, vol. 107, pp. 4317–4322, 3 2, 2010 2010.
- [8]. Meier JD, Oliver DA, and Varvares MA, "Surgical margin determination in head and neck oncology: current clinical practice. The results of an International American Head and Neck Society Member Survey," Head Neck, vol. 27, pp. 952–8, 11 2005. [PubMed: 16127669]

- [9]. Gandour-Edwards RF, Donald PJ, and Wiese DA, "Accuracy of intraoperative frozen section diagnosis in head and neck surgery: experience at a university medical center," *Head Neck*, vol. 15, pp. 33–8, Jan-Feb 1993. [PubMed: 8416854]
- [10]. Warram JM, de Boer E, Moore LS, Schmalbach CE, Withrow KP, Carroll WR, et al., "A ratiometric threshold for determining presence of cancer during fluorescence-guided surgery," *J Surg Oncol*, vol. 112, pp. 2–8, 7 2015. [PubMed: 26074273]
- [11]. Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, et al., "Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer," *Clin Cancer Res*, vol. 21, pp. 3658–66, 8 15 2015. [PubMed: 25904751]
- [12]. Hirche C, Engel H, Kolios L, Cognie J, Hunerbein M, Lehnhardt M, et al., "An experimental study to evaluate the Fluobeam 800 imaging system for fluorescence-guided lymphatic imaging and sentinel node biopsy," *Surg Innov*, vol. 20, pp. 516–23, 10 2013. [PubMed: 23275469]
- [13]. van der Vorst JR, Schaafsma BE, Verbeek FPR, Swijnenburg R, Tummers Q, Hutteman M, et al., "Intraoperative near-infrared fluorescence imaging of parathyroid adenomas with use of low-dose methylene blue," *Head Neck*, 5 29; 2013.
- [14]. Schaafsma BE, Verbeek FP, Rietbergen DD, van der Hiel B, van der Vorst JR, Liefers GJ, et al., "Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer," *Br J Surg*, vol. 100, pp. 1037–44, 7 2013. [PubMed: 23696463]
- [15]. Tummers Q, Hoogstins CES, Peters AAW, de Kroon CD, Trimboos J, van de Velde CJH, et al., "The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer," *PLoS One*, vol. 10, p. e0129766, 2015. [PubMed: 26110901]
- [16]. Rosenthal EL and Zinn KR, "Putting numbers to fluorescent guided surgery," *Mol Imaging Biol*, vol. 15, pp. 647–8, 12 2013. [PubMed: 23836503]
- [17]. Wolfe WL, *Introduction to imaging spectrometers* vol. 25: SPIE Press, 1997.
- [18]. Goetz AFH, "Three decades of hyperspectral remote sensing of the Earth: A personal view," *Remote Sensing of Environment*, vol. 113, Supplement 1, pp. S5–S16, 2009.
- [19]. Govender M, Chetty K, and Bulcock H, "A review of hyperspectral remote sensing and its application in vegetation and water resource studies," *Water SA*, vol. 33, 2007.
- [20]. Adam E, Mutanga O, and Rugege D, "Multispectral and hyperspectral remote sensing for identification and mapping of wetland vegetation: a review," *Wetlands Ecology and Management*, vol. 18, pp. 281–296, 2010/6/01 2010.
- [21]. Gowen AA, O'Donnell CP, Cullen PJ, Downey G, and Frias JM, "Hyperspectral imaging – an emerging process analytical tool for food quality and safety control," *Trends in Food Science & Technology*, vol. 18, pp. 590–598, 2007.
- [22]. Feng YZ and Sun DW, "Application of hyperspectral imaging in food safety inspection and control: a review," *Crit Rev Food Sci Nutr*, vol. 52, pp. 1039–58, 2012. [PubMed: 22823350]
- [23]. Edelman GJ, Gaston E, van Leeuwen TG, Cullen PJ, and Aalders MCG, "Hyperspectral imaging for non-contact analysis of forensic traces," *Forensic Science International*, vol. 223, pp. 28–39, 11/30/2012. [PubMed: 23088824]
- [24]. Malkoff DB and Oliver WR, "Hyperspectral imaging applied to forensic medicine," in *Proc. SPIE 3920, Spectral Imaging: Instrumentation, Applications, and Analysis*, 2000, pp. 108–116.
- [25]. Carrasco O, Gomez RB, Chainani A, and Roper WE, "Hyperspectral imaging applied to medical diagnoses and food safety," in *Proc. SPIE 5097, Geo-Spatial and Temporal Image and Data Exploitation III*, 2003, pp. 215–221.
- [26]. Afromowitz MA, Callis JB, Heimbach DM, DeSoto LA, and Norton MK, "Multispectral imaging of burn wounds: a new clinical instrument for evaluating burn depth," *Biomedical Engineering, IEEE Transactions on*, vol. 35, pp. 842–850, 1988.
- [27]. Zonios G, Perelman LT, Backman V, Manoharan R, Fitzmaurice M, Van Dam J, et al., "Diffuse Reflectance Spectroscopy of Human Adenomatous Colon Polyps In Vivo," *Applied Optics*, vol. 38, pp. 6628–6637, 1999/11/01 1999. [PubMed: 18324198]
- [28]. Wang LV and Wu H-I, "Introduction," in *Biomedical Optics*, ed: John Wiley & Sons, Inc., 2009, pp. 1–15.

- [29]. Costas B, Christos P, and George E, "Multi/Hyper-Spectral Imaging," in Handbook of Biomedical Optics, ed: CRC Press, 2011, pp. 131–164.
- [30]. Tuchin VV and Tuchin V, Tissue optics: light scattering methods and instruments for medical diagnosis vol. 13: SPIE press Bellingham, 2007.
- [31]. Ferris DG, Lawhead RA, Dickman ED, Holtzapple N, Miller JA, Grogan S, et al., "Multimodal Hyperspectral Imaging for the Noninvasive Diagnosis of Cervical Neoplasia," Journal of Lower Genital Tract Disease, vol. 5, pp. 65–72, 2001. [PubMed: 17043578]
- [32]. Pierce MC, Schwarz RA, Bhattar VS, Mondrik S, Williams MD, Lee JJ, et al., "Accuracy of In Vivo Multimodal Optical Imaging for Detection of Oral Neoplasia," Cancer Prevention Research, vol. 5, pp. 801–809, 6 1, 2012 2012. [PubMed: 22551901]
- [33]. Lu G and Fei B, "Medical hyperspectral imaging: a review," J Biomed Opt, vol. 19, p. 10901, 1 2014. [PubMed: 24441941]
- [34]. Lu G, Halig L, Wang D, Chen ZG, and Fei B, "Spectral-spatial classification using tensor modeling for cancer detection with hyperspectral imaging," in Proc. SPIE 9034, Medical Imaging 2014: Image Processing, 2014, p. 903413.
- [35]. Lu G, Halig L, Wang D, Chen ZG, and Fei B, "Hyperspectral imaging for cancer surgical margin delineation: registration of hyperspectral and histological images," in Proc. SPIE 9036, Medical Imaging 2014: Image-Guided Procedures, Robotic Interventions, and Modeling, 2014, p. 90360S.
- [36]. Halig LV, Wang D, Wang AY, Chen ZG, and Fei B, "Biodistribution Study of Nanoparticle Encapsulated Photodynamic Therapy Drugs Using Multispectral Imaging," Proc SPIE, vol. 8672, p. 867218, 3 29 2013.
- [37]. Hellebust A, Rosbach K, Wu JK, Nguyen J, Gillenwater A, Vigneswaran N, et al., "Vital-dye-enhanced multimodal imaging of neoplastic progression in a mouse model of oral carcinogenesis," J Biomed Opt, vol. 18, p. 126017, 12; 2013. [PubMed: 24362926]
- [38]. Lu G, Wang D, Qin X, Halig L, Muller S, Zhang H, et al., "Framework for hyperspectral image processing and quantification for cancer detection during animal tumor surgery," J Biomed Opt, vol. 20, p. 126012, 12 1 2015. [PubMed: 26720879]

Fig. 1.
The flowchart of the hyperspectral image processing, feature extraction, classification and validation.

Fig. 2. Fresh surgical specimens of tumor, normal tissue, and tumor with adjacent normal tissue from a tongue cancer patient. After the hyperspectral image acquisition, the average spectral curves of the three types of tissue are shown on the right, indicating the difference in their spectra.

Fig. 3.

Surgical specimens from a tongue cancer patient. *Left:* Photograph and histological images of the tumor, normal tissue, and the tumor with adjacent normal tissue. *Right:* Hyperspectral reflectance composite image, autofluorescence image, the fluorescence images with the vital dyes 2-NBDG and Proflavine of the same tissue specimens. Although a single HSI composite image may visually look similar as the other three images, the quantitative analysis and classification of the hundreds of bands from HSI data are able to provide a tumor map at the pixel level.